{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:09:42Z","timestamp":1790770182827,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":406,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41379-021-00885-9","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T06:03:10Z","timestamp":1628575390000},"page":"2183-2191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["EZH2 expression is associated with inferior overall survival in mantle cell lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Diana","family":"Martinez-Baquero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-7562","authenticated-orcid":false,"given":"Ali","family":"Sakhdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6029-458X","authenticated-orcid":false,"given":"Huan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-2618","authenticated-orcid":false,"given":"Do Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0523","authenticated-orcid":false,"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-8932","authenticated-orcid":false,"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis P.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-5464","authenticated-orcid":false,"given":"Roberto N.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-7880","authenticated-orcid":false,"given":"Chi Young","family":"Ok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-021-00885-9_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1038\/s41379-021-00885-9_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1038\/s41379-021-00885-9_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccr.2011.06.016","article-title":"Coordinated regulation of polycomb group complexes through microRNAs in cancer","volume":"20","author":"Cao","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1038\/s41379-021-00885-9_bib6","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1158\/1078-0432.CCR-13-2499","article-title":"Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination","volume":"20","author":"Ezponda","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1038\/s41379-021-00885-9_bib7","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1093\/nar\/gkq244","article-title":"Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes","volume":"38","author":"Pasini","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1038\/s41379-021-00885-9_bib8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1038\/s41379-021-00885-9_bib9","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"10.1038\/s41379-021-00885-9_bib10","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1038\/s41379-021-00885-9_bib12","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1038\/s41379-021-00885-9_bib13","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"10.1038\/s41379-021-00885-9_bib14","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-021-00885-9_bib15","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib16","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib17","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am. J. Hematol"},{"key":"10.1038\/s41379-021-00885-9_bib19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1038\/s41379-021-00885-9_bib20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"10.1038\/s41379-021-00885-9_bib21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2019002385","article-title":"Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing","volume":"136","author":"Pararajalingam","year":"2020","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib22","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib23","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/PAS.0000000000001312","article-title":"Mantle cell lymphoma involving skin: a clinicopathologic study of 37 cases","volume":"43","author":"Kim","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1038\/s41379-021-00885-9_bib24","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood.V97.12.3896","article-title":"Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma","volume":"97","author":"van Kemenade","year":"2001","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00428-013-1428-y","article-title":"In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2","volume":"463","author":"Abd Al Kader","year":"2013","journal-title":"Virchows Arch."},{"key":"10.1038\/s41379-021-00885-9_bib26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1046\/j.1365-2141.2001.02641.x","article-title":"The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma","volume":"112","author":"Visser","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1038\/s41379-021-00885-9_bib27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib28","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical, A.","year":"2013","journal-title":"JAMA"},{"key":"10.1038\/s41379-021-00885-9_bib29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1038\/s41379-021-00885-9_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1038\/s41379-021-00885-9_bib32","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2016.114","article-title":"Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1\/2 and MYC in aggressive B-cell lymphomas","volume":"29","author":"Tian","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00885-9_bib33","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.21873\/anticanres.13577","article-title":"Wedelolactone targets EZH2-mediated Histone H3K27 methylation in mantle cell lymphoma","volume":"39","author":"Romanchikova","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1038\/s41379-021-00885-9_bib34","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4161\/epi.26546","article-title":"A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma","volume":"8","author":"Kanduri","year":"2013","journal-title":"Epigenetics"},{"key":"10.1038\/s41379-021-00885-9_bib35","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3389\/fonc.2020.01226","article-title":"Deregulation of polycomb repressive complex-2 in mantle cell lymphoma confers growth advantage by epigenetic suppression of cdkn2b","volume":"10","author":"Demosthenous","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1038\/s41379-021-00885-9_bib36","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jamaoncol.2016.0021","article-title":"EZH2, proliferation rate, and aggressive tumor subtypes in cutaneous basal cell carcinoma","volume":"2","author":"Rao","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-021-00885-9_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1038\/s41379-021-00885-9_bib38","first-page":"4309","article-title":"Aberrant expression of EZH2 is associated with pathological findings and P53 alteration","volume":"33","author":"Shiogama","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1038\/s41379-021-00885-9_bib39","doi-asserted-by":"crossref","unstructured":"Zhang, H. M., Chen, S. Q. & Yao, S. Z. Expression and clinical implications of enhancer of Zeste homolog 2 and p53 protein in squamous cell carcinoma and precancerous lesions in the cervix. Genet. Mol. Res. 15, gmr.15027408 (2016).","DOI":"10.4238\/gmr.15027408"},{"key":"10.1038\/s41379-021-00885-9_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2214","article-title":"EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer","volume":"10","author":"Pietersen","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1038\/s41379-021-00885-9_bib41","doi-asserted-by":"crossref","unstructured":"Zhao, Y. et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J.38, e99599 (2019).","DOI":"10.15252\/embj.201899599"},{"key":"10.1038\/s41379-021-00885-9_bib42","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"10.1038\/s41379-021-00885-9_bib43","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1038\/s41379-021-00885-9_bib45","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","article-title":"Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers","volume":"43","author":"Lee","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1038\/s41379-021-00885-9_bib46","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"10.1038\/s41379-021-00885-9_bib47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2018.01.008","article-title":"CCRK is a novel signalling hub exploitable in cancer immunotherapy","volume":"186","author":"Mok","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1038\/s41379-021-00885-9_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/187152012800617678","article-title":"The role of Cdc25A in the regulation of cell proliferation and apoptosis","volume":"12","author":"Shen","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1038\/s41379-021-00885-9_bib49","doi-asserted-by":"crossref","first-page":"35946","DOI":"10.18632\/oncotarget.9371","article-title":"The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia","volume":"7","author":"Papakonstantinou","year":"2016","journal-title":"Oncotarget"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00885-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00885-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222003799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222003799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00885-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:33:19Z","timestamp":1760229199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222003799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0893395222003799"],"URL":"https:\/\/doi.org\/10.1038\/s41379-021-00885-9","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH2 expression is associated with inferior overall survival in mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-021-00885-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}